載入中
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
前收盤價
US$82.37
−US$0.06 · -0.07%
盤中時間採用ET。市場資料可能有所延遲。
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
日內區間
目前US$82.37
52週區間
目前US$82.37
盤中時間採用ET。市場資料可能有所延遲。
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
日內區間
目前US$82.37
52週區間
目前US$82.37
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 203.6萬 USD | 623.5萬 USD | 282.6萬 USD | 641.7萬 USD | 147.6萬 USD |
| 毛利 | 203.6萬 USD | 623.5萬 USD | 282.6萬 USD | 641.7萬 USD | 147.6萬 USD |
| 研究與開發 | 1.46億 USD | 8310.5萬 USD | 3284.1萬 USD | 2937.9萬 USD | 1260.6萬 USD |
| 銷售、一般及管理費用 | 3433.1萬 USD | 2499.4萬 USD | 1815.9萬 USD | 674.3萬 USD | 195.6萬 USD |
| 營業費用 | 1.8億 USD | 1.08億 USD | 5100萬 USD | 3612.2萬 USD | 1456.2萬 USD |
| 利息收入 | 1611.9萬 USD | 1736.5萬 USD | 476.4萬 USD | 114.5萬 USD | 10萬 USD |
| 折舊和攤銷 | 42.8萬 USD | 41.2萬 USD | 35.5萬 USD | 14.7萬 USD | 202萬 USD |
| 營業利益 | −1.78億 USD | −1.02億 USD | −4817.4萬 USD | −2970.5萬 USD | −1308.6萬 USD |
| 淨利 | −1.62億 USD | −8496.9萬 USD | −4355.5萬 USD | −2847.6萬 USD | −1310.9萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$132.6
上漲空間 60.98%| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2023年9月12日 | 1:16 | — | — |
已生效 2023年9月12日
1:16
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1.75億0.01%2.3兆 USD0.03%US$381.94+0.63%
State Street SPDR S&P Biotech ETFXBI1.15億1.17%98.74億 USD0.35%US$153.77+3.00%
iShares Russell 2000 ETFIWM1.03億0.13%787.4億 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF4897.67萬0.05%954億 USD0.05%US$235+0.80%
iShares Russell 2000 Growth ETFIWO3603.06萬0.26%139.17億 USD0.24%US$356.78+0.94%
Vanguard Russell 2000 ETFVTWO2872.44萬0.16%180億 USD0.06%US$112.66+0.50%
Schwab U.S. Small-Cap ETFSCHA2450.23萬0.11%218.24億 USD0.03%US$32.79+0.40%
T. Rowe Capital Appreciation Equity ETFTCAF1323.16萬0.15%91.1億 USD0.31%US$43.59+0.90%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAT. Rowe Capital Appreciation Equity ETFTCAFAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
